UK | Biocidal Products Regulation Set for Revisions: Emphasizing Scientific Progress, Reducing Animal Testing, and Ensuring Safety
The Great Britain Biocidal Products Regulation (GB BPR) is undergoing revisions to Annexes II and III, which pertain to the information requirements for biocidal active substances and biocidal products, respectively. The proposed changes aim to align GB BPR with the scientific and technical progress seen in the European Biocidal Products Regulation (EU BPR) while minimizing additional compliance costs for businesses.
The revisions emphasize the use of in vitro studies over in vivo studies, introduce new tests for endocrine disruptors as part of the legal data requirements, update requirements for mutagenicity, reproductive toxicity, and generational studies, and include developmental neurotoxicity studies under specific triggers. These changes seek to reduce animal testing, align with current guidance and OECD validated tests, and keep up with scientific advancements.
Although most of the changes align with the EU BPR, there are some differences. The proposed GB BPR revisions include additional impurities in the analytical information requirement for in situ generated active substances, exclude efficacy data for treated articles at the active substance evaluation stage, and specify developmental neurotoxicity testing only when triggered by certain conditions. These differences reflect the need for consistency, the focus on innate activity during efficacy assessment, and a more targeted approach to developmental neurotoxicity studies.
MORE INFO AND DOCUMENT: chemycal.com